AMOXAPINE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for amoxapine and what is the scope of patent protection?
Amoxapine
is the generic ingredient in two branded drugs marketed by Chartwell Rx, Watson Labs, Watson Pharms Teva, and Lederle, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.There are four drug master file entries for amoxapine. Two suppliers are listed for this compound.
Summary for AMOXAPINE
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 4 |
| NDAs: | 7 |
| Drug Master File Entries: | 4 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 117 |
| Clinical Trials: | 4 |
| Patent Applications: | 6,585 |
| Drug Prices: | Drug price trends for AMOXAPINE |
| What excipients (inactive ingredients) are in AMOXAPINE? | AMOXAPINE excipients list |
| DailyMed Link: | AMOXAPINE at DailyMed |
Recent Clinical Trials for AMOXAPINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
| Federal University of São Paulo | Phase 4 |
| Alexza Pharmaceuticals, Inc. | Phase 1 |
Pharmacology for AMOXAPINE
| Drug Class | Tricyclic Antidepressant |
Medical Subject Heading (MeSH) Categories for AMOXAPINE
Anatomical Therapeutic Chemical (ATC) Classes for AMOXAPINE
US Patents and Regulatory Information for AMOXAPINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lederle | ASENDIN | amoxapine | TABLET;ORAL | 018021-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lederle | ASENDIN | amoxapine | TABLET;ORAL | 018021-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs | AMOXAPINE | amoxapine | TABLET;ORAL | 072691-004 | Aug 28, 1992 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Chartwell Rx | AMOXAPINE | amoxapine | TABLET;ORAL | 072879-002 | Jun 28, 1991 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lederle | ASENDIN | amoxapine | TABLET;ORAL | 018021-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Pharms Teva | AMOXAPINE | amoxapine | TABLET;ORAL | 072420-001 | May 11, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Pharms Teva | AMOXAPINE | amoxapine | TABLET;ORAL | 072421-001 | May 11, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AMOXAPINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lederle | ASENDIN | amoxapine | TABLET;ORAL | 018021-004 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Lederle | ASENDIN | amoxapine | TABLET;ORAL | 018021-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Lederle | ASENDIN | amoxapine | TABLET;ORAL | 018021-003 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Lederle | ASENDIN | amoxapine | TABLET;ORAL | 018021-004 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Lederle | ASENDIN | amoxapine | TABLET;ORAL | 018021-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Lederle | ASENDIN | amoxapine | TABLET;ORAL | 018021-003 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Lederle | ASENDIN | amoxapine | TABLET;ORAL | 018021-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
